What does biomarker testing for ER, PR, and HER2 mean in breast cancer

Understanding Biomarker Testing: ER, PR, and HER2

Biomarker testing is one of the most important parts of your breast cancer evaluation. These tests look for specific proteins on your cancer cells that help your doctors understand what type of breast cancer you have and which treatments are most likely to work for you.

What Are These Biomarkers?

ER (Estrogen Receptor) and PR (Progesterone Receptor) are proteins that respond to hormones in your body. Think of them like locks on the surface of cancer cells—when estrogen or progesterone (hormones your body naturally makes) attach to these locks, they can signal the cancer cells to grow.

HER2 (Human Epidermal Growth Factor Receptor 2) is a different type of protein that also promotes cancer cell growth, but it works through a different pathway.

How the Testing Works

According to the NCCN Guidelines for Patients, your pathology report will show whether your cancer cells have these receptors. The testing uses a special staining process called immunohistochemistry (IHC), which adds chemical markers to your cancer cells so doctors can see these proteins under a microscope.

For ER and PR specifically:

• ER-positive (ER+) means your cancer cells have estrogen receptors in at least 1 out of every 100 cancer cells
• ER-low positive means receptors are found in only 1-10 out of every 100 cancer cells
• ER-negative (ER-) means few or no estrogen receptors are present

The same applies to PR testing.

Why This Matters for Treatment

These results directly guide your treatment options:

If you're ER+ and/or PR+ (Hormone Receptor-Positive): According to NCCN Guidelines, hormone receptor-positive breast cancer is typically treated with endocrine therapy (also called hormone therapy). These are medications that either block estrogen from attaching to receptors or reduce the amount of estrogen your body produces. This is a very different approach than chemotherapy.

If you're ER- and PR- (Hormone Receptor-Negative): Your cancer doesn't respond to hormone-blocking therapy, so your treatment team will consider other options, which may include chemotherapy or targeted therapies depending on other factors.

If you're HER2-positive: Your cancer cells have extra HER2 proteins, which means targeted therapies designed to block HER2 (like trastuzumab/Herceptin) may be particularly effective for you.

If you're HER2-negative: Your cancer doesn't have the extra HER2 proteins, so HER2-targeted drugs wouldn't be appropriate.

The Clinical Picture

According to NCCN Guidelines, these biomarkers are just one piece of your treatment planning puzzle. Your doctors will also consider:

• Your cancer stage (how large it is and whether it has spread)
• Your overall health and performance status
• Your age and other personal factors
• Whether you have other genetic mutations (like BRCA)

Questions to Ask Your Care Team

Since biomarker testing is so important for your treatment plan, here are specific questions to discuss with your oncologist:

1. What are my specific ER, PR, and HER2 results? (Ask for the exact percentages or scores)
2. What do these results mean for my treatment options?
3. Will I be receiving hormone therapy, HER2-targeted therapy, chemotherapy, or a combination?
4. Are there any other biomarker tests you recommend for my specific situation?
5. How will these results affect my long-term treatment plan?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.